217 related articles for article (PubMed ID: 30429453)
1. Clinical significance of APOB inactivation in hepatocellular carcinoma.
Lee G; Jeong YS; Kim DW; Kwak MJ; Koh J; Joo EW; Lee JS; Kah S; Sim YE; Yim SY
Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30429453
[TBL] [Abstract][Full Text] [Related]
2. Low
Yim SY; Kang SH; Shin JH; Jeong YS; Sohn BH; Um SH; Lee JS
Cells; 2020 Sep; 9(9):. PubMed ID: 32878261
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma.
Sohn BH; Shim JJ; Kim SB; Jang KY; Kim SM; Kim JH; Hwang JE; Jang HJ; Lee HS; Kim SC; Jeong W; Kim SS; Park ES; Heo J; Kim YJ; Kim DG; Leem SH; Kaseb A; Hassan MM; Cha M; Chu IS; Johnson RL; Park YY; Lee JS
Clin Cancer Res; 2016 Mar; 22(5):1256-64. PubMed ID: 26459179
[TBL] [Abstract][Full Text] [Related]
4. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
5. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
[TBL] [Abstract][Full Text] [Related]
6. Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma.
Gérard C; Di-Luoffo M; Gonay L; Caruso S; Couchy G; Loriot A; Castven D; Tao J; Konobrocka K; Cordi S; Monga SP; Hanert E; Marquardt JU; Zucman-Rossi J; Lemaigre FP
J Hepatol; 2019 Aug; 71(2):323-332. PubMed ID: 30953666
[TBL] [Abstract][Full Text] [Related]
7. A gene expression signature of FOXM1 predicts the prognosis of hepatocellular carcinoma.
Song BN; Chu IS
Exp Mol Med; 2018 Jan; 50(1):e418. PubMed ID: 29303511
[TBL] [Abstract][Full Text] [Related]
8. Insights into the etiology-associated gene regulatory networks in hepatocellular carcinoma from The Cancer Genome Atlas.
Seshachalam VP; Sekar K; Hui KM
J Gastroenterol Hepatol; 2018 Dec; 33(12):2037-2047. PubMed ID: 29672926
[TBL] [Abstract][Full Text] [Related]
9. miR-192-5p Silencing by Genetic Aberrations Is a Key Event in Hepatocellular Carcinomas with Cancer Stem Cell Features.
Gu Y; Wei X; Sun Y; Gao H; Zheng X; Wong LL; Jin L; Liu N; Hernandez B; Peplowska K; Zhao X; Zhan QM; Feng XH; Tang ZY; Ji J
Cancer Res; 2019 Mar; 79(5):941-953. PubMed ID: 30530815
[TBL] [Abstract][Full Text] [Related]
10. Reveal the molecular signatures of hepatocellular carcinoma with different sizes by iTRAQ based quantitative proteomics.
Wang Y; Liu H; Liang D; Huang Y; Zeng Y; Xing X; Xia J; Lin M; Han X; Liao N; Liu X; Liu J
J Proteomics; 2017 Jan; 150():230-241. PubMed ID: 27693406
[TBL] [Abstract][Full Text] [Related]
11. A signature of 33 immune-related gene pairs predicts clinical outcome in hepatocellular carcinoma.
Sun XY; Yu SZ; Zhang HP; Li J; Guo WZ; Zhang SJ
Cancer Med; 2020 Apr; 9(8):2868-2878. PubMed ID: 32068352
[TBL] [Abstract][Full Text] [Related]
12. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
[TBL] [Abstract][Full Text] [Related]
13. Analysis of microarrays of miR-34a and its identification of prospective target gene signature in hepatocellular carcinoma.
Ren FH; Yang H; He RQ; Lu JN; Lin XG; Liang HW; Dang YW; Feng ZB; Chen G; Luo DZ
BMC Cancer; 2018 Jan; 18(1):12. PubMed ID: 29298665
[TBL] [Abstract][Full Text] [Related]
14. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
Zhao QJ; Zhang J; Xu L; Liu FF
World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
[TBL] [Abstract][Full Text] [Related]
15. Clinical and biological significance of transcription termination factor, RNA polymerase I in human liver hepatocellular carcinoma.
Komatsu H; Iguchi T; Ueda M; Nambara S; Saito T; Hirata H; Sakimura S; Takano Y; Uchi R; Shinden Y; Eguchi H; Masuda T; Sugimachi K; Eguchi H; Doki Y; Mori M; Mimori K
Oncol Rep; 2016 Apr; 35(4):2073-80. PubMed ID: 26821084
[TBL] [Abstract][Full Text] [Related]
16. Exploration and validation of a novel prognostic signature based on comprehensive bioinformatics analysis in hepatocellular carcinoma.
Wang X; Qiao J; Wang R
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33111935
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a 14-gene signature for prognosis prediction in hepatocellular carcinoma.
Zhang BH; Yang J; Jiang L; Lyu T; Kong LX; Tan YF; Li B; Zhu YF; Xi AY; Xu X; Yan LN; Yang JY
Genomics; 2020 Jul; 112(4):2763-2771. PubMed ID: 32198063
[TBL] [Abstract][Full Text] [Related]
18. RRAD inhibits aerobic glycolysis, invasion, and migration and is associated with poor prognosis in hepatocellular carcinoma.
Shang R; Wang J; Sun W; Dai B; Ruan B; Zhang Z; Yang X; Gao Y; Qu S; Lv X; Tao K; Wang L; Dou K; Wang D
Tumour Biol; 2016 Apr; 37(4):5097-105. PubMed ID: 26546438
[TBL] [Abstract][Full Text] [Related]
19. Identification of a four-gene metabolic signature predicting overall survival for hepatocellular carcinoma.
Liu GM; Xie WX; Zhang CY; Xu JW
J Cell Physiol; 2020 Feb; 235(2):1624-1636. PubMed ID: 31309563
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma.
Zhang XF; Chao J; Pan QZ; Pan K; Weng DS; Wang QJ; Zhao JJ; He J; Liu Q; Jiang SS; Chen CL; Zhang HX; Xia JC
Oncotarget; 2015 Dec; 6(38):40920-33. PubMed ID: 26506518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
